Exceptional Response to Pembrolizumab in a Mismatch Repair-Deficient Aggressive Prostate Cancer with Somatic EPCAM, MSH2, and MSH6 Co-Deletion: A Case Report

Mismatch repair-deficient (dMMR) prostate cancer (PCa) is a rare (1–5%) but highly actionable molecular subgroup of PCa, vulnerable to immune checkpoint inhibitors. Our case of sporadic dMMR PCa due to large monoallelic co-deletion of EPCAM, MSH2, and MSH6 features a clinically aggressive disease pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoch, Dennis, Rabaglio, Manuela, Grob, Tobias, von Gunten, Michael, Beyer, Jörg, Akhoundova, Dilara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622161/
https://www.ncbi.nlm.nih.gov/pubmed/37928863
http://dx.doi.org/10.1159/000534177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622161/
https://www.ncbi.nlm.nih.gov/pubmed/37928863
http://dx.doi.org/10.1159/000534177

Ejemplares similares